Clinical Trials | November 27, 2025
NHS’s breakthrough leukaemia therapy set to transform lives in UK
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Subscribe To Our Newsletter & Stay Updated
